SGLT2 Inhibitors in Type 2 Diabetes Linked to Lower Risk of Developing GI Cancers

Damian McNamara, MAVANCOUVER, Canada — Use of sodium glucose cotransporter-2 (SGLT2) inhibitors is associated with a reduced risk of gastrointestinal (GI) cancers among patients withtype 2 diabe

Updated on: October 27,2023

SGLT2 Inhibitors in Type 2 Diabetes Linked to Lower Risk of Developing GI Cancers

Damian McNamara, MAVANCOUVER, Canada — Use of sodium glucose cotransporter-2 (SGLT2) inhibitors is associated with a reduced risk of gastrointestinal (GI) cancers among patients withtype 2 diabe

Updated on:October 27,2023

Success of Rhabdomyosarcoma Treatment in Children

Including Rarer Types of RMS Disease in AdultsByJaime R. Herndon, MS, MPHPublished on July 03, 2023Medically reviewed byDoru Paul, MDRhabdomyosarcomais a kind ofsar

Updated on: November 21,2023

Success of Rhabdomyosarcoma Treatment in Children

Including Rarer Types of RMS Disease in AdultsByJaime R. Herndon, MS, MPHPublished on July 03, 2023Medically reviewed byDoru Paul, MDRhabdomyosarcomais a kind ofsar

Updated on:November 21,2023

What to Know About Blood Typing

What to Know About Blood TypingByNancy LeBrunPublished on July 14, 2023Medically reviewed bySteffini Stalos, DOYourblood typeis categorized by certain substances on

Updated on: March 17,2024

What to Know About Blood Typing

What to Know About Blood TypingByNancy LeBrunPublished on July 14, 2023Medically reviewed bySteffini Stalos, DOYourblood typeis categorized by certain substances on

Updated on:March 17,2024

AI tool reveals cardiac risk for patients undergoing cancer therapy

byYale School of MedicineBaseline AI-ECG screening for LVSD and all-cause mortality risk. Adjusted cumulative hazard curves for all-cause mortality stratified by the AI-ECG LVSD probability. Cre

Updated on: September 27,2024

AI tool reveals cardiac risk for patients undergoing cancer therapy

byYale School of MedicineBaseline AI-ECG screening for LVSD and all-cause mortality risk. Adjusted cumulative hazard curves for all-cause mortality stratified by the AI-ECG LVSD probability. Cre

Updated on:September 27,2024

Who Gets Laryngeal (Voice Box) Cancer?

Dysplasia means precancerous, which isn’t cancer yet, but it could progressByAnna GiorgiPublished on July 24, 2023Medically reviewed byBenjamin F. Asher, MDLaryngeal cancer, al

Updated on: November 21,2023

Who Gets Laryngeal (Voice Box) Cancer?

Dysplasia means precancerous, which isn’t cancer yet, but it could progressByAnna GiorgiPublished on July 24, 2023Medically reviewed byBenjamin F. Asher, MDLaryngeal cancer, al

Updated on:November 21,2023

EMA Grants PRIME Designation to Iopofosine I-131 for Waldenström Macroglobulinemia

September 18, 2023Kristi RosaThe European Medicines Agency has granted Priority Medicines designation to iopofosine I-131 for use in patients with Waldenström macroglobulinemia in patients who previou

Updated on: October 11,2023

EMA Grants PRIME Designation to Iopofosine I-131 for Waldenström Macroglobulinemia

September 18, 2023Kristi RosaThe European Medicines Agency has granted Priority Medicines designation to iopofosine I-131 for use in patients with Waldenström macroglobulinemia in patients who previou

Updated on:October 11,2023

What Is Bloom Syndrome?

What Is Bloom Syndrome?ByCristina MutchlerPublished on August 16, 2021Medically reviewed byLyndsey Garbi, MDBloom syndrome, or Bloom's syndrome, is an extremely rareg

Updated on: March 17,2024

What Is Bloom Syndrome?

What Is Bloom Syndrome?ByCristina MutchlerPublished on August 16, 2021Medically reviewed byLyndsey Garbi, MDBloom syndrome, or Bloom's syndrome, is an extremely rareg

Updated on:March 17,2024

How Successful Is Immunotherapy for Breast Cancer?

ByMaxine LipnerPublished on August 18, 2023Medically reviewed byDoru Paul, MDImmunotherapycan boost your body's immune response to cancer cells and hopefully kill the

Updated on: November 20,2023

How Successful Is Immunotherapy for Breast Cancer?

ByMaxine LipnerPublished on August 18, 2023Medically reviewed byDoru Paul, MDImmunotherapycan boost your body's immune response to cancer cells and hopefully kill the

Updated on:November 20,2023

European Approval Sought for Amivantamab Plus Chemo in EGFR Exon 20 Insertion+ NSCLC

October 6, 2023Kristi RosaA Type II extension of indication application seeking the approval of amivantamab in combination with carboplatin and pemetrexed for the frontline treatment of adult patients

Updated on: October 09,2023

European Approval Sought for Amivantamab Plus Chemo in EGFR Exon 20 Insertion+ NSCLC

October 6, 2023Kristi RosaA Type II extension of indication application seeking the approval of amivantamab in combination with carboplatin and pemetrexed for the frontline treatment of adult patients

Updated on:October 09,2023

Cancer survivor feared recurrence, but this time it was his heart

Heart attack survivor Doug Cobb. Photo: Caitriona CobbDoug Cobb popped a couple antacid pills to calm the heartburn he'd been experiencing on and off for weeks. The 60-year-old considered he might

Updated on: December 10,2023

Cancer survivor feared recurrence, but this time it was his heart

Heart attack survivor Doug Cobb. Photo: Caitriona CobbDoug Cobb popped a couple antacid pills to calm the heartburn he'd been experiencing on and off for weeks. The 60-year-old considered he might

Updated on:December 10,2023

The crosstalk between glucose metabolism and epigenetics in cardiac aging and cancer adaptation

Updated on: August 29,2024

The crosstalk between glucose metabolism and epigenetics in cardiac aging and cancer adaptation

Updated on:August 29,2024

Dostarlimab Plus Chemo Wins MHRA Approval for dMMR/MSI-H Primary Advanced/Recurrent

October 6, 2023Ashling WahnerThe Medicines and Healthcare Products Regulatory Agency has authorized the use of dostarlimab in combination with chemotherapy for the treatment of patients with mismatch

Updated on: October 09,2023

Dostarlimab Plus Chemo Wins MHRA Approval for dMMR/MSI-H Primary Advanced/Recurrent

October 6, 2023Ashling WahnerThe Medicines and Healthcare Products Regulatory Agency has authorized the use of dostarlimab in combination with chemotherapy for the treatment of patients with mismatch

Updated on:October 09,2023